2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3-4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1-3-dione and Huntington-Disease

2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3-4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1-3-dione has been researched along with Huntington-Disease* in 1 studies

Other Studies

1 other study(ies) available for 2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3-4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1-3-dione and Huntington-Disease

Article	Year
Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging. Neurology, 2016, Feb-23, Volume: 86, Issue:8 To evaluate whether striatal [(18)F]MNI-659 PET imaging of phosphodiesterase 10A (PDE10) serves as a sensitive and reliable biomarker of striatal neurodegeneration in a longitudinal cohort of participants with early Huntington disease (HD).. A cohort of participants with HD, including both participants premanifest or manifest with motor signs, underwent clinical assessments, genetic determination, and 2 [(18)F]MNI-659 PET imaging sessions approximately 1 year apart. Eleven healthy control (HC) participants underwent clinical assessments and [(18)F]MNI-659 PET imaging once. Striatal binding potentials (BPnd) were estimated for brain regions of interest, specifically within the basal ganglia, and compared between baseline and follow-up imaging. Clinical measures of HD severity were assessed at each visit.. Eight participants with HD (6 manifest; 2 premanifest) participated. Of those with manifest HD, all had relatively early stage disease (stage 1, n = 2; stage 2, n = 4) and a Unified Huntington's Disease Rating Scale total motor score <45. As expected, the HD cohort as a whole had a reduction in the basal ganglia BPnd to approximately 50% of that seen in HC. On follow-up scans, [(18)F]MNI-659 uptake declined in the putamen and caudate nucleus in all 8 participants. The mean annualized rates of decline in signal in the caudate, putamen, and globus pallidus and the putamen were 16.6%, 6.9%, and 5.8%, respectively. In HC, the annualized reduction in signal in striatal regions was less than 1%.. Longitudinal data in this small cohort of participants with early HD support [(18)F]MNI-659 PET imaging of PDE10 as a useful biomarker to track HD disease progression. Topics: Adult; Aged; Biomarkers; Cohort Studies; Disease Progression; Female; Fluorine Radioisotopes; Humans; Huntington Disease; Longitudinal Studies; Male; Middle Aged; Phosphoric Diester Hydrolases; Phthalimides; Positron-Emission Tomography; Quinazolinones	2016

Article

Year

Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.

Neurology, 2016, Feb-23, Volume: 86, Issue:8

To evaluate whether striatal [(18)F]MNI-659 PET imaging of phosphodiesterase 10A (PDE10) serves as a sensitive and reliable biomarker of striatal neurodegeneration in a longitudinal cohort of participants with early Huntington disease (HD).. A cohort of participants with HD, including both participants premanifest or manifest with motor signs, underwent clinical assessments, genetic determination, and 2 [(18)F]MNI-659 PET imaging sessions approximately 1 year apart. Eleven healthy control (HC) participants underwent clinical assessments and [(18)F]MNI-659 PET imaging once. Striatal binding potentials (BPnd) were estimated for brain regions of interest, specifically within the basal ganglia, and compared between baseline and follow-up imaging. Clinical measures of HD severity were assessed at each visit.. Eight participants with HD (6 manifest; 2 premanifest) participated. Of those with manifest HD, all had relatively early stage disease (stage 1, n = 2; stage 2, n = 4) and a Unified Huntington's Disease Rating Scale total motor score <45. As expected, the HD cohort as a whole had a reduction in the basal ganglia BPnd to approximately 50% of that seen in HC. On follow-up scans, [(18)F]MNI-659 uptake declined in the putamen and caudate nucleus in all 8 participants. The mean annualized rates of decline in signal in the caudate, putamen, and globus pallidus and the putamen were 16.6%, 6.9%, and 5.8%, respectively. In HC, the annualized reduction in signal in striatal regions was less than 1%.. Longitudinal data in this small cohort of participants with early HD support [(18)F]MNI-659 PET imaging of PDE10 as a useful biomarker to track HD disease progression.

Topics: Adult; Aged; Biomarkers; Cohort Studies; Disease Progression; Female; Fluorine Radioisotopes; Humans; Huntington Disease; Longitudinal Studies; Male; Middle Aged; Phosphoric Diester Hydrolases; Phthalimides; Positron-Emission Tomography; Quinazolinones

2016